Clinical-stage biotechnology company developing targeted therapies for oncology and inflammatory disease by identifying and targeting disease-associated cell states and cell-state plasticity
Clinical-stage biotechnology company developing targeted therapies for oncology and inflammatory disease by identifying and targeting disease-associated cell states and cell-state plasticity. Its AURIGIN platform combines proprietary single-cell genomic data with AI/ML-powered computational analysis to identify disease drivers, therapeutic targets, models, and biomarkers. Lead program AUTX-703 is advancing toward clinical development for cancers including acute myeloid leukemia, small-cell lung,